Clinical Trial Update: Biweekly Gemcitabine and Docetaxel as First Line Therapy for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update investigating biweekly gemcitabine and docetaxel as first-line therapy for advanced non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: Hospital Arnau de Vilanova | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: UNKNOWN